Nexstim: Toward a year of new openings
In H2, Nexstim's net sales were well below our estimates while the operating loss was in line with our expectation. We lowered our net sales estimates for the next few years but left our longer-term growth expectations unchanged. Our EBIT estimates rise with a better profitability outlook. The valuation picture is more attractive than before with the outlook and lower share price.
Nexstim
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures2023-02-28
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 9.5 | 7.4 | 9.9 |
growth-% | 48.91 % | -21.81 % | 33.54 % |
EBIT (adj.) | 0.8 | -1.2 | 0.3 |
EBIT-% (adj.) | 8.79 % | -16.41 % | 2.76 % |
EPS (adj.) | 0.18 | -0.18 | 0.02 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | 22.85 | - | 109.52 |
EV/EBITDA | 22.00 | - | 25.41 |